355 related articles for article (PubMed ID: 17905096)
1. p63 gene expression study and early bladder carcinogenesis.
Compérat E; Bièche I; Dargère D; Ferlicot S; Laurendeau I; Benoît G; Vieillefond A; Verret C; Vidaud M; Capron F; Bedossa P; Paradis V
Urology; 2007 Sep; 70(3):459-62. PubMed ID: 17905096
[TBL] [Abstract][Full Text] [Related]
2. Quantitative detection of cytokeratin 20 mRNA expression in bladder carcinoma by real-time reverse transcriptase-polymerase chain reaction.
Christoph F; Müller M; Schostak M; Soong R; Tabiti K; Miller K
Urology; 2004 Jul; 64(1):157-61. PubMed ID: 15245962
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of p63 isoforms in normal tissues and neoplastic cells.
Nylander K; Vojtesek B; Nenutil R; Lindgren B; Roos G; Zhanxiang W; Sjöström B; Dahlqvist A; Coates PJ
J Pathol; 2002 Dec; 198(4):417-27. PubMed ID: 12434410
[TBL] [Abstract][Full Text] [Related]
4. [Construction of deltaNp63 specific small hairpin RNA expressing plasmid and its role in bladder cancer--a preliminary study].
He YF; Wu XH; Luo CL; Tian DY; Zhang LS; Gao F
Zhonghua Zhong Liu Za Zhi; 2006 Nov; 28(11):820-5. PubMed ID: 17416002
[TBL] [Abstract][Full Text] [Related]
5. Activation of RAS family genes in urothelial carcinoma.
Boulalas I; Zaravinos A; Karyotis I; Delakas D; Spandidos DA
J Urol; 2009 May; 181(5):2312-9. PubMed ID: 19303097
[TBL] [Abstract][Full Text] [Related]
6. Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma.
Tsui KH; Cheng AJ; Chang Pe; Pan TL; Yung BY
Urology; 2004 Oct; 64(4):839-44. PubMed ID: 15491744
[TBL] [Abstract][Full Text] [Related]
7. Dominant negative p63 isoform expression in head and neck squamous cell carcinoma.
Sniezek JC; Matheny KE; Westfall MD; Pietenpol JA
Laryngoscope; 2004 Dec; 114(12):2063-72. PubMed ID: 15564824
[TBL] [Abstract][Full Text] [Related]
8. Expression of lung resistance-related protein in transitional cell carcinoma of bladder.
Zhu Y; Kong C; Zeng Y; Sun Z; Gao H
Urology; 2004 Apr; 63(4):694-8. PubMed ID: 15072883
[TBL] [Abstract][Full Text] [Related]
9. DeltaNp63 isoforms regulate CD44 and keratins 4, 6, 14 and 19 in squamous cell carcinoma of head and neck.
Boldrup L; Coates PJ; Gu X; Nylander K
J Pathol; 2007 Dec; 213(4):384-91. PubMed ID: 17935121
[TBL] [Abstract][Full Text] [Related]
10. Uroplakin gene expression in normal human tissues and locally advanced bladder cancer.
Olsburgh J; Harnden P; Weeks R; Smith B; Joyce A; Hall G; Poulsom R; Selby P; Southgate J
J Pathol; 2003 Jan; 199(1):41-9. PubMed ID: 12474225
[TBL] [Abstract][Full Text] [Related]
11. The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurrence of p63 gene amplification.
Pruneri G; Fabris S; Dell'Orto P; Biasi MO; Valentini S; Del Curto B; Laszlo D; Cattaneo L; Fasani R; Rossini L; Manzotti M; Bertolini F; Martinelli G; Neri A; Viale G
J Pathol; 2005 Jul; 206(3):337-45. PubMed ID: 15887287
[TBL] [Abstract][Full Text] [Related]
12. Identification of differentially expressed genes in human bladder cancer through genome-wide gene expression profiling.
Kawakami K; Enokida H; Tachiwada T; Gotanda T; Tsuneyoshi K; Kubo H; Nishiyama K; Takiguchi M; Nakagawa M; Seki N
Oncol Rep; 2006 Sep; 16(3):521-31. PubMed ID: 16865252
[TBL] [Abstract][Full Text] [Related]
13. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status.
Maas S; Warskulat U; Steinhoff C; Mueller W; Grimm MO; Schulz WA; Seifert HH
Urology; 2004 Feb; 63(2):392-7. PubMed ID: 14972509
[TBL] [Abstract][Full Text] [Related]
14. Methylation patterns of Rb1 and Casp-8 promoters and their impact on their expression in bladder cancer.
Malekzadeh K; Sobti RC; Nikbakht M; Shekari M; Hosseini SA; Tamandani DK; Singh SK
Cancer Invest; 2009 Jan; 27(1):70-80. PubMed ID: 19160091
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma.
Zigeuner R; Tsybrovskyy O; Ratschek M; Rehak P; Lipsky K; Langner C
Urology; 2004 Jun; 63(6):1079-83. PubMed ID: 15183954
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the gene expression of SPARC and its prognostic value for bladder cancer.
Yamanaka M; Kanda K; Li NC; Fukumori T; Oka N; Kanayama HO; Kagawa S
J Urol; 2001 Dec; 166(6):2495-9. PubMed ID: 11696817
[TBL] [Abstract][Full Text] [Related]
17. Utility of urothelial mRNA markers in blood for staging and monitoring bladder cancer.
Marín-Aguilera M; Mengual L; Ribal MJ; Ars E; Ríos J; Gázquez C; Villavicencio H; Alcaraz A
Urology; 2012 Jan; 79(1):240.e9-15. PubMed ID: 22055693
[TBL] [Abstract][Full Text] [Related]
18. Frequent alteration of p63 expression in human primary bladder carcinomas.
Park BJ; Lee SJ; Kim JI; Lee SJ; Lee CH; Chang SG; Park JH; Chi SG
Cancer Res; 2000 Jul; 60(13):3370-4. PubMed ID: 10910040
[TBL] [Abstract][Full Text] [Related]
19. Real-time quantitative analysis for human telomerase reverse transcriptase mRNA and human telomerase RNA component mRNA expressions as markers for clinicopathologic parameters in urinary bladder cancer.
Takihana Y; Tsuchida T; Fukasawa M; Araki I; Tanabe N; Takeda M
Int J Urol; 2006 Apr; 13(4):401-8. PubMed ID: 16734859
[TBL] [Abstract][Full Text] [Related]
20. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]